Summary
In order to estimate the cumulative incidence rates of the mucopolysaccharidoses (MPS) in Germany, a retrospective epidemiological survey covering the period between 1980 and 1995 was implemented. Multiple ascertainment sources were used to identify affected patients. A prevalence of approximately 0.69 cases per 100 000 births was obtained for MPS I (Hurler phenotype). Within the study period, 4 patients with Hurler/Scheie phenotype and 7 cases with Scheie disease were detected. The cumulative incidence for MPS II (Hunter syndrome) was estimated as 0.64 cases per 100 000 births (1.3 cases per 100 000 male live births); that for MPS III (Sanfilippo syndrome types A, B and C) as 1.57 cases in 100 000 births; that for MPS IV A (Morquio syndrome) as 0.38 cases in 100 000; and that for MPS VI (Maroteaux–Lamy syndrome) as 0.23 cases per 100 000 births. Two cases of MPS IVB (β-galactosidase deficiency) have been identified, but no patients with MPS VII or MPS IX. A relatively high number of patients with MPS IIIB, MPS IVA and MPS VI were of Turkish origin. The crude rate for all types of mucopolysaccharidoses is approximately 3.53 cases in 100 000 live births. The cumulative incidence pattern of MPS in Germany was compared with the corresponding rates among other industrial nations obtained from recent literature: the crude cumulative rates for all types of mucopolysaccharidoses (3.4–4.5 in 100 000 live births) were similar among all published populations; however, different frequencies of the various forms of MPS were observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics 105: e10.
Breslow N, Day N (1987) The design and analysis of cohort studies. In: Statistical Methods in Cancer Research, vol. II. Lyon: IARC Publications.
Bunge S, Kleijer WJ, Steglich C, et al (1994) Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet 3: 861–866.
Bunge S, Kleijer WJ, Steglich C, Beck M, Schwinger E, Gal A (1995) Mucopolysaccharidosis type I: identification of 13 novel mutations of the alpha-L-iduronidase gene. Hum Mutat 6: 91–94.
Coelho JC, Wajner M, Burin MG, Vargas CR, Giugliani R (1997) Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur J Pediatr 156: 650–654.
Cornel MC (1999) Common language for measures of occurrence of congenital anomalies and genetic diseases: incidence or birth prevalence. Community Genet 2: 162–164.
Desnick RJ (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27: 385–410.
Diamond JM (1994) Human genetics. Jewish lysosomes. Nature 368: 291–292.
Emre S, Terzioglu M, Coskun T, et al (2002) Biochemical and molecular analysis of mucopolysaccharidoses in Turkey. Turk J Pediatr 44: 13–17.
Lowry RB, Renwick DH (1971) Relative frequency of the Hurler and Hunter syndromes. N Engl J Med 284: 221–222.
Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY (1990) An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet 85: 389–390.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281: 249–254.
Michelakakis H, Dimitriou E, Tsagaraki S, Giouroukos S, Schulpis K, Bartsocas CS (1995) Lysosomal storage diseases in Greece. Genet Couns 6: 43–47.
Nelson J (1997) Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 101: 355–358.
Nelson J, Crowhurst J, Carey B, Greed L (2003) Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet 123A: 310–313.
Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105: 151–156.
Poupetova H (2003) Prevalence of lysosomal storage disorders in the Czech and Slovak Republics. ESGLD Workshop, Podebrady, Czech Republic. Sponsoring Organization: European Study Group on Lysosomal Diseases.
Schaap T, Bach G (1980) Incidence of mucopolysaccharidoses in Israel: is Hunter disease a “Jewish disease”? Hum Genet 56: 221–223.
Triggs-Raine B, Salo TJ, Zhang H, Wicklow BA, Natowicz MR (1999) Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci USA 96: 6296–6300.
Van de Kamp JJP (1979) The Sanfilippo syndrome: a clinical and genetical study of 75 patients in The Netherlands. Thesis: University of Leiden.
Vervoort R, Islam MR, Sly WS, et al (1996) Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII. Am J Hum Genet 58: 457–471.
Vervoort R, Gitzelmann R, Bosshard N, Maire I, Liebaers I, Lissens W (1998) Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote. Hum Genet 102: 69–78.
Weber B, Guo XH, Kleijer WJ, van de Kamp JJ, Poorthuis BJ, Hopwood JJ (1999) Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet 7: 34–44.
Yogalingam G, Hopwood JJ (2001) Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat 18: 264–281.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baehner, F., Schmiedeskamp, C., Krummenauer, F. et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28, 1011–1017 (2005). https://doi.org/10.1007/s10545-005-0112-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10545-005-0112-z